Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor… Read more
Oric Pharmaceuticals Inc (ORIC) - Total Liabilities
Latest total liabilities as of September 2025: $24.27 Million USD
Based on the latest financial reports, Oric Pharmaceuticals Inc (ORIC) has total liabilities worth $24.27 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oric Pharmaceuticals Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Oric Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Oric Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Oric Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PORR AG
VI:POS
|
Austria | €3.57 Billion |
|
Shenzhen Click Technology Co Ltd
SHE:002782
|
China | CN¥2.63 Billion |
|
Peakstone Realty Trust
NYSE:PKST
|
USA | $1.21 Billion |
|
Fujian Furi Electronics Co Ltd
SHG:600203
|
China | CN¥6.72 Billion |
|
Koppers Holdings Inc
NYSE:KOP
|
USA | $1.31 Billion |
|
Anhui Huaheng Biotechnology Co. Ltd. A
SHG:688639
|
China | CN¥3.00 Billion |
|
Apogee Enterprises Inc
NASDAQ:APOG
|
USA | $603.74 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Oric Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oric Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oric Pharmaceuticals Inc (2017–2024)
The table below shows the annual total liabilities of Oric Pharmaceuticals Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $31.02 Million | +1.38% |
| 2023-12-31 | $30.60 Million | +9.25% |
| 2022-12-31 | $28.01 Million | +9.12% |
| 2021-12-31 | $25.67 Million | +178.34% |
| 2020-12-31 | $9.22 Million | +50.69% |
| 2019-12-31 | $6.12 Million | -94.50% |
| 2018-12-31 | $111.16 Million | +2485.72% |
| 2017-12-31 | $4.30 Million | -- |